Abstract:Objective To observe the efficacy,side effect and health economics values of the therapy of antidepressants combining atypical antipsychotics with different administration lengths,on nonpsychotic symptom,treatment-resistant depression. Methods 99 patients out of the randomized 4 groups of patients completed one year follow-up study.The 4 groups are the group of single therapy of fluoxetine(27 patients),the group of therapy of fluoxetine combining 1~2 months administration of olanzapine(28 patients),the group of therapy of fluoxetine combining 4~6 months administration of olanzapine(29 patients) and the group of therapy of fluoxetine combining 12 months administration of olanzapine(15 patients).At the starting point,measure of all patients in the four groups the HAMD,SDSS,weight and annual income ete at the end of 1 year follow-up study,measure of those patients the HAMD,weight.TESS and income of the past year,working hours,recurrent frequency and therapeutic sosts etc.The decreased scores of HAMD tests and the cure rates are used to evaluate the efficacy,the TESS scores and weight records are used to evaluate the side effect,and the working hours,annual income and therapeutic costs are used to evaluate the health economics values. Results All patients of the four groups improved at different degree comparing to their pre-therapeutic period.The group of therapy of fluoxetine combining 4~6 months administration of olanzapine and the group of therapy of fluoxetine combining 12 months administration of olanzapine were improved more significantly than the other two groups.No patients in the four groups showed severe side effects,but patients of the three groups of combination therapy had weight increase at different degree comparing with the fluoxetine single using group.In terms of annual income,working hours and recurrent frequency,the 4~6 months olanzapine combination group and the 12 months olanzapine combination group are superior to the other two groups.The 4~6 months olanzapine combination group is at lower therapeutic cost than the 12 months olanzapine combination group. Conclusions Therapy of olanzapine,the atypical antipsychotics,combining fluoxetine on nonpsychotic symptom,treatment-resistant depression has definite curative effect and less side effects.The most appropricate administration length of olanzapine in the combination is 4~6 months..

The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia

Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period.

Olanzapine add-on treatment promotes neuronal differentiation of neural stem cells compared with fluoxetine alone

Adjunctive Treatment of Brexpiprazole with Fluoxetine Shows a Rapid Antidepressant Effect in Social Defeat Stress Model: Role of BDNF-TrkB Signaling

Combined sulforaphane and β-sitosterol mitigate olanzapine-induced metabolic disorders in rats: Insights on FOXO, PI3K/AKT, JAK/STAT3, and MAPK signaling pathways

P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats

A study of olanzapine and fluoxetine combination therapy on nonpsychotic symptom,treatment-resistant depression

Olanzapine Ameliorates Neuropathological Changes and Increases IGF-1 Expression in Frontal Cortex of C57BL/6 Mice Exposed to Cuprizone.

The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers.

The Interplay between MiR-134/BDNF and LKB1/AMPK/SIRT1 Accentuates the Antidepressant Efficacy of Empagliflozin in Ovariectomized Rats

Cannabidiol as an add-on therapy to overcome the slow-onset and, possibly, resistance to antidepressant treatment: involvement of NAPE-PLD in the medial prefrontal cortex

Involvement of PI3K/Akt/FoxO3a and PKA/CREB Signaling Pathways in the Protective Effect of Fluoxetine Against Corticosterone-Induced Cytotoxicity in PC12 Cells

Rapid Eye Movement Sleep Deprivation Combined With Fluoxetine Protects Against Depression-Induced Damage and Apoptosis in Rat Hippocampi via A1 Adenosine Receptor

Brain Antioxidant Effect of Mirtazapine and Reversal of Sedation by Its Combination with Alpha-Lipoic Acid in a Model of Depression Induced by Corticosterone

Modulatory effect of olanzapine on neuronal nitric oxide synthase (nNOS) expression in the rat striatum

Randomized Double-Blind Control Study of Olanzapine Augmented with Fluoxetine for Schizophrenia with Depression Symptom

Brain-derived neurotrophic factor modulation in response to oxidative stress and corticosterone: Role of scopolamine and mirtazapine

The effect of paroxetine, venlafaxine and bupropion administration alone and combined on spatial and aversive memory performance in rats

Antidepressant Effects of Combination of Brexpiprazole and Fluoxetine on Depression-Like Behavior and Dendritic Changes in Mice after Inflammation